

BEGIN MSDS ESIPB132

-----  
SECTION 1        CHEMICAL PRODUCT AND COMPANY IDENTIFICATION  
-----

ESI-LEDERLE GENERICS  
P.O. BOX 8299  
PHILADELPHIA, PA 19101  
610-688-4400

24 HR. EMERGENCY MEDICAL INFORMATION:  
610-688-4400  
CHEMTREC(R) USA, CAN, PR: 800-424-9300  
INTERNATIONAL: 202-483-7616

SUBSTANCE: CHLORPROMAZINE HYDROCHLORIDE

TRADE NAMES/SYNONYMS:  
CHLORPROMAZINE HYDROCHLORIDE INJECTION; ESIPB132

PRODUCT USE: PHARMACEUTICAL

CREATION DATE: NOV 01 1991  
REVISION DATE: APR 16 2001

-----  
SECTION 2        COMPOSITION, INFORMATION ON INGREDIENTS  
-----

COMPONENT: CHLORPROMAZINE HYDROCHLORIDE  
CAS NUMBER: 69-09-0  
EC NUMBER (EINECS): 200-701-3  
PERCENTAGE: 2.6

COMPONENT: WATER  
CAS NUMBER: 7732-18-5  
EC NUMBER (EINECS): 231-791-2  
PERCENTAGE: >1

-----  
SECTION 3        HAZARDS IDENTIFICATION  
-----

NFPA RATINGS (SCALE 0-4): HEALTH=4 FIRE=0 REACTIVITY=0

EMERGENCY OVERVIEW:

PHYSICAL DESCRIPTION: CLEAR, COLORLESS SOLUTION.

MAJOR HEALTH HAZARDS: POTENTIALLY FATAL IF INHALED, HARMFUL IF SWALLOWED,  
CENTRAL NERVOUS SYSTEM DEPRESSION

POTENTIAL HEALTH EFFECTS:

INHALATION:

SHORT TERM EXPOSURE: IRRITATION, DEATH

LONG TERM EXPOSURE: NO INFORMATION IS AVAILABLE

SKIN CONTACT:

SHORT TERM EXPOSURE: IRRITATION

LONG TERM EXPOSURE: NO INFORMATION IS AVAILABLE

EYE CONTACT:

SHORT TERM EXPOSURE: IRRITATION

LONG TERM EXPOSURE: NO INFORMATION IS AVAILABLE

INGESTION:

SHORT TERM EXPOSURE: DROWSINESS, SYMPTOMS OF DRUNKENNESS, FAINTING,

IRREGULAR HEARTBEAT, ALLERGIC REACTIONS

LONG TERM EXPOSURE: NO INFORMATION ON SIGNIFICANT ADVERSE EFFECTS

CARCINOGEN STATUS:

OSHA: NO

NTP: NO

IARC: NO

-----  
SECTION 4        FIRST AID MEASURES  
-----

INHALATION: IF ADVERSE EFFECTS OCCUR, REMOVE TO UNCONTAMINATED AREA. GIVE  
ARTIFICIAL RESPIRATION IF NOT BREATHING. GET IMMEDIATE MEDICAL ATTENTION.

SKIN CONTACT: WASH SKIN WITH SOAP AND WATER FOR AT LEAST 15 MINUTES WHILE  
REMOVING CONTAMINATED CLOTHING AND SHOES. GET MEDICAL ATTENTION, IF NEEDED.

THOROUGHLY CLEAN AND DRY CONTAMINATED CLOTHING AND SHOES BEFORE REUSE.

EYE CONTACT: FLUSH EYES WITH PLENTY OF WATER FOR AT LEAST 15 MINUTES. THEN GET IMMEDIATE MEDICAL ATTENTION.

INGESTION: IF SWALLOWED, DRINK PLENTY OF WATER, DO NOT INDUCE VOMITING. GET IMMEDIATE MEDICAL ATTENTION. INDUCE VOMITING ONLY AT THE INSTRUCTIONS OF A PHYSICIAN. DO NOT GIVE ANYTHING BY MOUTH TO UNCONSCIOUS OR CONVULSIVE PERSON.

NOTE TO PHYSICIAN: FOR INGESTION, CONSIDER GASTRIC LAVAGE, ACTIVATED CHARCOAL SLURRY AND CATHARSIS.

---

SECTION 5 FIRE FIGHTING MEASURES

---

FIRE AND EXPLOSION HAZARDS: NO HAZARD EXPECTED.

EXTINGUISHING MEDIA: USE EXTINGUISHING AGENTS APPROPRIATE FOR SURROUNDING FIRE.

LARGE FIRES: USE REGULAR FOAM OR FLOOD WITH FINE WATER SPRAY.

FIRE FIGHTING: MOVE CONTAINER FROM FIRE AREA IF IT CAN BE DONE WITHOUT RISK. AVOID INHALATION OF MATERIAL OR COMBUSTION BY-PRODUCTS. STAY UPWIND AND KEEP OUT OF LOW AREAS.

FLASH POINT: NO DATA AVAILABLE.

---

SECTION 6 ACCIDENTAL RELEASE MEASURES

---

OCCUPATIONAL RELEASE:  
DO NOT TOUCH SPILLED MATERIAL. ABSORB WITH SAND OR OTHER NON-COMBUSTIBLE MATERIAL. COLLECT SPILLED MATERIAL IN APPROPRIATE CONTAINER FOR DISPOSAL.

---

SECTION 7 HANDLING AND STORAGE

---

STORAGE: STORE AND HANDLE IN ACCORDANCE WITH ALL CURRENT REGULATIONS AND STANDARDS. KEEP SEPARATED FROM INCOMPATIBLE SUBSTANCES. SEE ORIGINAL CONTAINER FOR STORAGE RECOMMENDATIONS.

---

SECTION 8 EXPOSURE CONTROLS, PERSONAL PROTECTION

---

EXPOSURE LIMITS:  
CHLORPROMAZINE HYDROCHLORIDE:  
NO OCCUPATIONAL EXPOSURE LIMITS ESTABLISHED.

VENTILATION: UNDER NORMAL CONDITIONS OF USE, NO SPECIAL VENTILATION EQUIPMENT IS NEEDED.

EYE PROTECTION: EYE PROTECTION NOT REQUIRED, BUT RECOMMENDED.

CLOTHING: UNDER NORMAL CONDITIONS OF USE, WEAR SUITABLE CLOTHING TO PREVENT CONTACT WITH SKIN.

GLOVES: WEAR APPROPRIATE CHEMICAL RESISTANT GLOVES.

RESPIRATOR: NO RESPIRATOR IS REQUIRED UNDER NORMAL CONDITIONS OF USE. UNDER CONDITIONS OF FREQUENT USE OR HEAVY EXPOSURE, RESPIRATORY PROTECTION MAY BE NEEDED.

RESPIRATORY PROTECTION IS RANKED IN ORDER FROM MINIMUM TO MAXIMUM.  
CONSIDER WARNING PROPERTIES BEFORE USE.

ANY DUST AND MIST RESPIRATOR.

ANY AIR-PURIFYING RESPIRATOR WITH A HIGH-EFFICIENCY PARTICULATE FILTER.  
FOR UNKNOWN CONCENTRATIONS OR IMMEDIATELY DANGEROUS TO LIFE OR HEALTH -  
ANY SUPPLIED-AIR RESPIRATOR WITH A FULL FACEPIECE THAT IS OPERATED IN A

PRESSURE-DEMAND OR OTHER POSITIVE-PRESSURE MODE.  
ANY SELF-CONTAINED BREATHING APPARATUS.

-----  
SECTION 9        PHYSICAL AND CHEMICAL PROPERTIES  
-----

PHYSICAL DESCRIPTION: CLEAR, COLORLESS SOLUTION.  
BOILING POINT: NOT AVAILABLE  
FREEZING POINT: NOT AVAILABLE  
VAPOR PRESSURE: NOT AVAILABLE  
VAPOR DENSITY: NOT AVAILABLE  
SPECIFIC GRAVITY: NOT AVAILABLE  
WATER SOLUBILITY: MISCIBLE  
PH: 3.4-5.4  
VOLATILITY: NOT AVAILABLE  
ODOR THRESHOLD: NOT AVAILABLE  
EVAPORATION RATE: NOT AVAILABLE  
COEFFICIENT OF WATER/OIL DISTRIBUTION: NOT AVAILABLE

-----  
SECTION 10       STABILITY AND REACTIVITY  
-----

REACTIVITY: STABLE AT NORMAL TEMPERATURES AND PRESSURE.

CONDITIONS TO AVOID: NONE REPORTED.

INCOMPATIBILITIES:  
MAY BE INCOMPATIBLE WITH ACIDS, BASES, AND OXIDIZERS.

HAZARDOUS DECOMPOSITION:  
THERMAL DECOMPOSITION PRODUCTS: MISCELLANEOUS DECOMPOSITION PRODUCTS

POLYMERIZATION: WILL NOT POLYMERIZE.

-----  
SECTION 11       TOXICOLOGICAL INFORMATION  
-----

CHLORPROMAZINE HYDROCHLORIDE:  
TOXICITY DATA:

6071 UG/KG ORAL-MAN TDLO; 6 MG/KG ORAL-WOMAN TDLO; 35 GM/KG/16 YEAR(S)  
INTERMITTENT ORAL-WOMAN TDLO; 1786 UG/KG/2 DAY(S) INTERMITTENT  
INTRAVENOUS-MAN TDLO; 822 UG/KG INTRAVENOUS-WOMAN TDLO; 145 MG/KG ORAL-RAT  
LD50; 40 MG/M3/2 HOUR(S) INHALATION-RAT LC50; 62 MG/KG INTRAPERITONEAL-RAT  
LD50; 25 MG/KG INTRAVENOUS-RAT LD50; 90 MG/KG UNREPORTED-RAT LD50; 135 MG/KG  
ORAL-MOUSE LD50; 40 MG/M3/2 HOUR(S) INHALATION-MOUSE LC50; 92200 UG/KG  
INTRAPERITONEAL-MOUSE LD50; 420 MG/KG SUBCUTANEOUS-MOUSE LD50; 20 MG/KG  
INTRAVENOUS-MOUSE LD50; >30 MG/KG ORAL-MONKEY LDLO; 5 MG/KG  
INTRAVENOUS-RABBIT LD50; 109 MG/KG INTRAPERITONEAL-GUINEA PIG LD50; 420  
MG/KG SUBCUTANEOUS-GUINEA PIG LD50; 160 MG/KG INTRAPERITONEAL-CHICKEN LD50;  
28 MG/KG INTRAVENOUS-CHICKEN LD50; 900 MG/KG/30 DAY(S) INTERMITTENT ORAL-RAT  
TDLO; 50 MG/KG/5 DAY(S) INTERMITTENT SUBCUTANEOUS-RAT TDLO

ACUTE TOXICITY LEVEL:

HIGHLY TOXIC: INHALATION  
TOXIC: INGESTION

TARGET ORGANS: CENTRAL NERVOUS SYSTEM

MUTAGENIC DATA:

MUTATION IN MICROORGANISMS - SALMONELLA TYPHIMURIUM 5 MG/L (-S9); MUTATION  
IN MICROORGANISMS - ESCHERICHIA COLI 5 MG/L (+S9); MUTATION IN  
MICROORGANISMS - ESCHERICHIA COLI 80 MG/L (-S9); DNA INHIBITION -  
ESCHERICHIA COLI 48 MG/L; OTHER MUTATION TEST SYSTEMS - ESCHERICHIA COLI 48  
MG/L; OTHER MUTATION TEST SYSTEMS - RAT INTRAPERITONEAL 25 MG/KG

REPRODUCTIVE EFFECTS DATA:

300 MG/KG ORAL-RAT TDLO 6-20 DAY(S) PREGNANT FEMALE CONTINUOUS; 50 MG/KG  
ORAL-RAT TDLO 7-16 DAY(S) PREGNANT FEMALE CONTINUOUS; 250 MG/KG ORAL-RAT  
TDLO 7-16 DAY(S) PREGNANT FEMALE CONTINUOUS; 350 MG/KG ORAL-RAT TDLO 7-16  
DAY(S) PREGNANT FEMALE CONTINUOUS; 1980 MG/KG ORAL-RAT TDLO 4 WEEK(S) MALE  
WEEK(S) PRE PREGNANCY/4 WEEK(S) POST PREGNANCY/3 WEEK(S) CONTINUOUS; 2500  
UG/KG INTRAPERITONEAL-RAT TDLO 1 DAY(S) MALE; 25 MG/KG INTRAPERITONEAL-RAT  
TDLO 8 DAY(S) PREGNANT FEMALE CONTINUOUS; 100 MG/KG INTRAPERITONEAL-RAT TDLO  
14 DAY(S) PREGNANT FEMALE CONTINUOUS; 100 MG/KG INTRAPERITONEAL-RAT TDLO 14

DAY(S) PREGNANT FEMALE CONTINUOUS; 50 MG/KG INTRAPERITONEAL-RAT TDLO 12  
DAY(S) PREGNANT FEMALE CONTINUOUS; 12 MG/KG SUBCUTANEOUS-RAT TDLO 12-15  
DAY(S) PREGNANT FEMALE CONTINUOUS; 24 MG/KG SUBCUTANEOUS-RAT TDLO 17-20  
DAY(S) PREGNANT FEMALE CONTINUOUS; 12 MG/KG SUBCUTANEOUS-RAT TDLO 12-15  
DAY(S) PREGNANT FEMALE CONTINUOUS; 24 MG/KG SUBCUTANEOUS-RAT TDLO 17-20  
DAY(S) PREGNANT FEMALE CONTINUOUS; 125 MG/KG SUBCUTANEOUS-RAT TDLO 5 DAY(S)  
MALE; 300 MG/KG ORAL-MOUSE TDLO 6-15 DAY(S) PREGNANT FEMALE CONTINUOUS; 300  
MG/KG ORAL-MOUSE TDLO 6-15 DAY(S) PREGNANT FEMALE CONTINUOUS; 150 MG/KG  
ORAL-MOUSE TDLO 6-15 DAY(S) PREGNANT FEMALE CONTINUOUS; 21 MG/KG  
SUBCUTANEOUS-MOUSE TDLO 9 DAY(S) PREGNANT FEMALE CONTINUOUS; 10 MG/KG  
SUBCUTANEOUS-MOUSE TDLO 3 DAY(S) PREGNANT FEMALE CONTINUOUS  
ADDITIONAL DATA: INTERACTIONS WITH DRUGS MAY OCCUR.

HEALTH EFFECTS:

INHALATION:

ACUTE EXPOSURE:

CHLORPROMAZINE HYDROCHLORIDE: MAY CAUSE IRRITATION.

CHRONIC EXPOSURE:

CHLORPROMAZINE HYDROCHLORIDE: NO DATA AVAILABLE.

SKIN CONTACT:

ACUTE EXPOSURE:

CHLORPROMAZINE HYDROCHLORIDE: MAY CAUSE IRRITATION.

CHRONIC EXPOSURE:

CHLORPROMAZINE HYDROCHLORIDE: NO DATA AVAILABLE.

EYE CONTACT:

ACUTE EXPOSURE:

CHLORPROMAZINE HYDROCHLORIDE: MAY CAUSE IRRITATION.

CHRONIC EXPOSURE:

CHLORPROMAZINE HYDROCHLORIDE: NO DATA AVAILABLE.

INGESTION:

ACUTE EXPOSURE:

CHLORPROMAZINE HYDROCHLORIDE: MAY CAUSE CENTRAL NERVOUS SYSTEM DEPRESSION WITH TRANSIENT DROWSINESS AND DIZZINESS. SMALL DOSES MAY CAUSE SYNCOPE, TACHYCARDIA, AND ALLERGIC REACTIONS. LARGE DOSES MAY CAUSE PARKINSONIAN SYNDROME SYMPTOMS SUCH AS DROOLING, TREMOR, RIGIDITY, ABNORMAL POSTURE AND GAIT, RESTLESSNESS, AND PROFUSE SPEECH. IN ADDITION, EXTRAPYRAMIDAL REACTIONS SUCH AS DYSKINESIA, DYSTONIA, CERVICAL MUSCLE SPASM, FACIAL MUSCLE SPASM, LACK OF CONTROL OF MOVEMENTS OF THE TONGUE, BIZARRE INVOLUNTARY MOVEMENTS OF THE EXTREMITIES AND DEPRESSED RESPIRATION MAY OCCUR. A RARE IDIOSYNCRATIC REACTION, NEUROLEPTIC MALIGNANT SYNDROME AND TRANSIENT JAUNDICE MAY ALSO OCCUR.

CHRONIC EXPOSURE:

CHLORPROMAZINE HYDROCHLORIDE: REPRODUCTIVE EFFECTS HAVE BEEN REPORTED IN ANIMALS.

-----  
SECTION 12 ECOLOGICAL INFORMATION  
-----

NOT AVAILABLE

-----  
SECTION 13 DISPOSAL CONSIDERATIONS  
-----

DISPOSE IN ACCORDANCE WITH ALL APPLICABLE REGULATIONS.

-----  
SECTION 14 TRANSPORT INFORMATION  
-----

U.S. DEPARTMENT OF TRANSPORTATION: NO CLASSIFICATION ASSIGNED.

CANADIAN TRANSPORTATION OF DANGEROUS GOODS: NO CLASSIFICATION ASSIGNED.

LAND TRANSPORT ADR/RID: NO CLASSIFICATION ASSIGNED.

AIR TRANSPORT IATA/ICAO: NO CLASSIFICATION ASSIGNED.

MARITIME TRANSPORT IMDG: NO CLASSIFICATION ASSIGNED.

-----  
SECTION 15 REGULATORY INFORMATION  
-----

U.S. REGULATIONS:

CERCLA SECTIONS 102A/103 HAZARDOUS SUBSTANCES (40 CFR 302.4): NOT REGULATED.

SARA TITLE III SECTION 302 EXTREMELY HAZARDOUS SUBSTANCES (40 CFR 355.30):  
NOT REGULATED.

SARA TITLE III SECTION 304 EXTREMELY HAZARDOUS SUBSTANCES (40 CFR 355.40):  
NOT REGULATED.

SARA TITLE III SARA SECTIONS 311/312 HAZARDOUS CATEGORIES (40 CFR 370.21):  
ACUTE: YES  
CHRONIC: NO  
FIRE: NO  
REACTIVE: NO  
SUDDEN RELEASE: NO

SARA TITLE III SECTION 313 (40 CFR 372.65): NOT REGULATED.

OSHA PROCESS SAFETY (29CFR1910.119): NOT REGULATED.

STATE REGULATIONS:

CALIFORNIA PROPOSITION 65: NOT REGULATED.

CANADIAN REGULATIONS:

WHMIS CLASSIFICATION: NOT DETERMINED.

EUROPEAN REGULATIONS:

EC CLASSIFICATION (CALCULATED): NOT DETERMINED.

NATIONAL INVENTORY STATUS:

U.S. INVENTORY (TSCA): EXEMPT.

TSCA 12(B) EXPORT NOTIFICATION: NOT LISTED.

-----  
SECTION 16 OTHER INFORMATION  
-----

COPYRIGHT 1984-2001 MDL INFORMATION SYSTEMS, INC. ALL RIGHTS RESERVED.

THE INFORMATION PROVIDED IN THIS MSDS IS BASED UPON SOURCES BELIEVED TO BE ACCURATE. HOWEVER, THE COMPANY ASSUMES NO RESPONSIBILITY FOR THE ACCURACY, COMPLETENESS OR SUITABILITY OF THIS INFORMATION. THE PRODUCT USER IS RESPONSIBLE TO DETERMINE THE SUITABILITY OF THIS INFORMATION FOR THEIR PARTICULAR PURPOSES.